Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir

Journal of Hepatology

Volumn 58, Issue 4, 2013, Pages 646-654

  Karino, Yoshiyasu ^a   Toyota, Joji ^a   Ikeda, Kenji ^b   Suzuki, Fumitaka ^b   Chayama, Kazuaki ^c   Kawakami, Yoshiiku ^c   Ishikawa, Hiroki ^d   Watanabe, Hideaki ^d   Hernandez, Dennis ^e   Yu, Fei ^e   McPhee, Fiona ^e   Kumada, Hiromitsu ^b  

^a Sapporo Kosei General Hospital   (Japan)

^b TORANOMON HOSPITAL   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d Bristol Myers KK   (Japan)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

Asunaprevir; Daclatasvir; Direct acting antivirals; Drug resistance; Hepatitis C; Peginterferon sparing

Indexed keywords

ASUNAPREVIR; DACLATASVIR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A; VIRUS RNA;

ADULT; AGED; AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; JAPANESE; MALE; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENES, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; ISOQUINOLINES; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RNA, VIRAL; SULFONAMIDES; TREATMENT FAILURE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84880931245     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.11.012     Document Type: Article

References (25)

1. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, and N.H. Bzowej Telaprevir for previously untreated chronic HCV infection N Engl J Med 364 2011 2405 2416
2. F. Poordad, J. McCone, B.R. Bacon, S. Bruno, M.P. Manns, and M.S. Sulkowski Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
3. M. Ghany, D.R. Nelson, D.B. Strader, D.L. Thomas, and L.B. Seeff An update on treatment of genotype 1 chronic HCV infection: 2011 practice guidelines by the American Association for the Study of Liver Diseases Hepatology 54 2011 1433 1444
4. Merck. VICTRELIS™ (boceprevir) [package insert]; 2012.
5. Vertex Pharmaceuticals. INCIVEK™ (telaprevir) [package insert]; 2012.
6. M. Gao, R.E. Nettles, M. Belema, L.B. Snyder, V.N. Nguyen, and R.A. Fridell Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature 465 2010 96 100
7. S. Pol, R.H. Ghalib, V.K. Rustgi, C. Martorell, G.T. Everson, and H.A. Tatum Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial Lancet Infect Dis 12 9 2012 671 677
8. F. McPhee, A.K. Sheaffer, J. Friborg, D. Hernandez, P. Falk, and G. Zhai Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032) Antimicrob Agents Chemother 56 2012 5387 5396
9. J.P. Bronowicki, S. Pol, P. Thuluvath, D. Larrey, C.T. Martorell, and V.K. Rustgi Asunaprevir (ASV; BMS-650032), an NS3 protease inhibitor, in combination with peginterferon and ribavirin in treatment-naive patients with genotype 1 chronic HCV infection J Hepatol 56 suppl 2 2012 S431 S432
10. K. Chayama, S. Takahashi, J. Toyota, Y. Karino, K. Ikeda, and H. Ishikawa Dual therapy with the NS5A inhibitor, daclatasvir, and the NS3 protease inhibitor, asunaprevir, in HCV genotype 1b-infected null responders Hepatology 55 2012 742 748
11. Suzuki Y, Ikeda K, Suzuki F, Toyota J, Karino Y, Chayama K, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol accepted for publication. http://dx.doi.org/10.1016/j.jhep.2012.09.037.
12. J.P. Bronowicki, S. Pol, P.J. Thuluvath, D. Larrey, C.T. Martorell, and V.K. Rustgi BMS-650032, an NS3 inhibitor, in combination with peginterferon alfa-2a and ribavirin in treatment-naive subjects with genotype 1 chronic HCV infection J Hepatol 54 suppl 1 2011 S472
13. R.A. Fridell, C. Wang, J.H. Sun, D.R. O'Boyle, P. Nower, and L. Valera Genotypic and phenotypic analysis of variants resistant to HCV NS5A replication complex inhibitor BMS-790052: in vitro and in vivo correlations Hepatology 54 2011 1924 1935
14. C. Pasquinelli, F. McPhee, T. Eley, C. Villegas, K. Sandy, and P. Wendelburg Single and multiple ascending dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C Antimicrob Agents Chemother 56 2012 1838 1844
15. A.K. Sheaffer, M.S. Lee, D. Hernandez, S. Chaniewski, F. Yu, and P. Falk Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates Antivir Ther 16 2011 705 718
16. R.A. Fridell, D. Qiu, C. Wang, L. Valera, and M. Gao Resistance analysis of the HCV NS5A inhibitor BMS-790052 in an in vitro replicon system Antimicrob Agents Chemother 54 2010 3641 3650
17. J.H. Sun, D.R. O'Boyle, Y. Zhang, C. Wang, P. Nower, and L. Valera Impact of a baseline polymorphism on the emergence of resistance to the HCV NS5A replication complex inhibitor BMS-790052 Hepatology 55 2012 1692 1699
18. O. Lenz, T. Verbinnen, T.I. Lin, L. Vijgen, M.D. Cummings, and J. Lindberg In vitro resistance profile of the HCV NS3/4A protease inhibitor TMC435 Antimicrob Agents Chemother 54 2010 1878 1887
19. F. McPhee, J. Friborg, S. Levine, C. Chen, P. Falk, and F. Yu Resistance analysis of the HCV NS3 protease inhibitor asunaprevir Antimicrob Agents Chemother 56 2012 3670 3681
20. C. Kuiken, K. Yusim, L. Boykin, and R. Richardson The Los Alamos hepatitis C sequence database Bioinformatics 21 2005 379 384 (Pubitemid 40246609)
21. F. McPhee, D. Hernandez, F. Yu, J. Ueland, K. Chayama, and J. Toyota A description of virologic escape in HCV genotype 1-infected patients treated with daclatasvir (BMS-790052) in combination with ribavirin and peginterferon-alfa- 2a or peginterferon-alfa-2b J Hepatol 56 suppl 2 2012 S473
22. J. Guedj, L. Rong, H. Dahari, and A.S. Perelson A perspective on modelling hepatitis C virus infection J Viral Hepat 17 2010 825 833
23. O. Lenz, J. de Bruijne, L. Vijgen, T. Verbinnen, C. Weegink, and H. Van Marck Efficacy of re-treatment with TMC-435 as combination therapy in HCV-infected patients following TMC-435 monotherapy Gastroenterology 143 2012 1176 1178 e6
24. T.L. Kieffer, S. De Meyer, D.J. Bartels, J.C. Sullivan, E.Z. Zhang, and A. Tigges Hepatitis C viral evolution in genotype 1 treatment-naive and treatment-experienced patients receiving telaprevir-based therapy in clinical trials PLoS One 7 2012 e34372
25. S. Susser, J. Vermehren, N. Forestier, M.W. Welker, N. Grigorian, and C. Füller Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir J Clin Virol 52 2011 321 327